# Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US

> **NCT00795093** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 552 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00795093
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2010-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00795093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00795093, "Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00795093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*